Eikon Therapeutics(EIKN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EIKN Eikon Therapeutics

交易中 03-19 14:19:00 EDT

11.34

-0.40

-3.41%

最高12.08	最低11.29	成交量16.09万
今开11.74	昨收11.74	日振幅6.73%
总市值6.12亿	流通市值2.00亿	总股本5,398万
成交额187.26万	换手率0.91%	流通股本1,765万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":11.34,"timestamp":1773944321375,"preClose":11.74,"halted":0,"volume":160859,"delay":0,"changeRate":-0.03407155025553665,"floatShares":17648000,"shares":53984300,"eps":-113.66688,"marketStatus":"交易中","change":-0.4,"latestTime":"03-19 14:19:00 EDT","open":11.74,"high":12.08,"low":11.29,"amount":1872606.428969,"amplitude":0.067291,"askPrice":11.37,"askSize":28,"bidPrice":11.32,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-113.66688,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773950400000},"marketStatusCode":2,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":11.74,"preHourTrading":{"tag":"盘前","latestPrice":11.68,"preClose":11.74,"latestTime":"09:05 EDT","volume":4161,"amount":52624.870209,"timestamp":1773925551393,"change":-0.06,"changeRate":-0.005111,"amplitude":0.245315},"postHourTrading":{"tag":"盘后","latestPrice":11.74,"preClose":11.74,"latestTime":"18:47 EDT","volume":14387,"amount":168903.84,"timestamp":1773874058108,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.565859},"requestUrl":"/m/hq/s/EIKN","defaultTab":"news","newsList":[{"id":"1136724466","title":"美银全球研究启动对Eikon Therapeutics的覆盖 给予买入评级及34美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1136724466","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136724466?lang=zh_cn&edition=full","pubTime":"2026-03-02 19:43","pubTimestamp":1772451794,"startTime":"0","endTime":"0","summary":"美银全球研究近日宣布，正式启动对生物科技公司Eikon Therapeutics（股票代码：EIKN）的研究覆盖，并首次给予\"买入\"评级。该机构同时设定了34美元的目标股价，显示出对该公司未来增长前景的积极预期。\n此次覆盖启动标志着华尔街主要机构对Eikon Therapeutics在创新药物开发领域技术实力的认可。分析师在报告中指出，公司独特的平台技术和研发管线布局为其长期价值提升奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"gpt_icon":0},{"id":"2609258870","title":"美股异动 | Eikon Therapeutics(EIKN.US)登陆纳斯达克 开盘跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609258870","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609258870?lang=zh_cn&edition=full","pubTime":"2026-02-06 00:13","pubTimestamp":1770308025,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，Eikon Therapeutics(EIKN.US)登陆纳斯达克，开盘跌超5%，报17.05美元，IPO价格为18美元。Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年创立，公司目前正布局多款癌症实验性疗法研发管线。公司研发进度最快的候选药物EIK1001，正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期临床试验，该研究的中期分析数据预计将于2026年下半年公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVIW.SI","QYLG","BK4581","USJW.SI","QYLD","UWM","QQQY","TZA","TSYW.SI","RWM","QLD","TWM","USAW.SI","PSQ","BK4534","BK4539","EIKN","BK4585","SQQQ","IWO","JEPQ","MNQmain","GPIQ","BK4535","SRTY","TNA","BK4550","BK4007","TQQQ","BK4588","BK1147","IWN","QID","QQQJ","QQQE","BK4139"],"gpt_icon":0},{"id":"2609326107","title":"生物医药公司Eikon Therapeutics(EIKN.US)IPO定价18美元募资3.812亿 今晚登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2609326107","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609326107?lang=zh_cn&edition=full","pubTime":"2026-02-05 15:14","pubTimestamp":1770275686,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物医药公司Eikon Therapeutics周三表示，其美国首次公开发行募资3.812亿美元，共发行约2120万股普通股，发行价定为每股18美元。而今年初，生物科技企业IPO同样迎来复苏，SpyGlass Pharma、AgomAb Therapeutics等生物医药研发企业均已在1月递交美国上市申请。Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年创立，公司目前正布局多款癌症实验性疗法研发管线。Eikon Therapeutics的股票将于周四在纳斯达克挂牌交易，股票代码为“EIKN”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"189b8e4ee2abd43b1a3c2e363b7669dc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"生物医药公司Eikon Therapeutics(EIKN.US)IPO定价18美元募资3.812亿 今晚登陆纳斯达克","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["JEPQ","PSQ","QLD","QQQE","TQQQ","QYLG","BK4007","USJW.SI","QQQY","TSYW.SI","GPIQ","BK1147","USAW.SI","BK4585","MNQmain","QID","QQQJ","BK4539","QYLD","EIKN","SQQQ","NVIW.SI","BK4139","BK4588"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.eikontx.com","stockEarnings":[{"period":"1week","weight":-0.1093},{"period":"1month","weight":-0.2199},{"period":"3month","weight":-0.3478},{"period":"ytd","weight":-0.3478}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Eikon Therapeutics, Inc.于2019年7月9日在特拉华州注册成立。该公司是一家后期临床生物制药公司，旨在开发创新药物，以解决重大未满足的医疗需求。该组织主要专注于肿瘤学，推进一系列候选药物，旨在满足大适应症内的高未满足需求。该领导班子有着成功研发有冲击力药物的显著历史。该公司的战略包括利用专有技术平台创造新疗法，其主要候选药物针对晚期黑色素瘤和非小细胞肺癌等严重疾病。","exchange":"NASDAQ","name":"Eikon Therapeutics","nameEN":"Eikon Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eikon Therapeutics(EIKN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Eikon Therapeutics(EIKN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Eikon Therapeutics,EIKN,Eikon Therapeutics股票,Eikon Therapeutics股票老虎,Eikon Therapeutics股票老虎国际,Eikon Therapeutics行情,Eikon Therapeutics股票行情,Eikon Therapeutics股价,Eikon Therapeutics股市,Eikon Therapeutics股票价格,Eikon Therapeutics股票交易,Eikon Therapeutics股票购买,Eikon Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eikon Therapeutics(EIKN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Eikon Therapeutics(EIKN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}